Encyclopedia entry
BPC-157
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-26
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · BPC-157
BPC-157 is a synthetic 15-amino-acid peptide derived from a fragment of a protein found in human gastric juice, first characterised by the Sikiric group at the University of Zagreb in the 1990s. Roughly 200 preclinical papers, almost all rodent models, suggest tissue-protective and pro-healing effects on tendon, gut and vascular tissue. No phase II or phase III human clinical trials have been published.
Top UK BPC-157 retailer
Mechanism of action
How BPC-157 works
BPC-157 is proposed to modulate the nitric oxide system, accelerate angiogenesis through upregulation of VEGF expression, and stabilise growth-hormone receptor signalling at the site of injury. In rodent tendon models it appears to encourage migration of fibroblasts to the injury site and to support early granulation. The exact receptor target in humans is not established.
What the literature shows (in animals)
Across roughly 200 preclinical papers published since 2003, BPC-157 has been reported to accelerate tendon healing by approximately 34% in rat models, to protect gut barrier integrity in rodent models of stress and inflammation, and to support angiogenesis in vascular ischaemia models. Independent replication outside the originating Zagreb group remains limited.
- · Tendon-healing acceleration in rat models (multiple papers, Sikiric group, 2003 onwards).
- · Gut barrier integrity protection in rodent models of stress and inflammation.
- · Vascular and angiogenesis effects in rodent ischaemia models.
- · Bone healing acceleration in rat fracture models.
- · Behavioural and central-nervous-system effects in rodent depression and Parkinsonian models.
Most of the literature comes from a single research group. Independent replication is limited. None of these findings have been confirmed in randomised human trials.
UK regulatory status
BPC-157 sits outside the Misuse of Drugs Act 1971 and outside the Psychoactive Substances Act 2016. It has zero UK marketing authorisations as a medicine. UK retailers can sell it lawfully only by labelling it for "research use only, not for human or animal consumption" and by avoiding any therapeutic claim.
- · Not a controlled drug under the Misuse of Drugs Act 1971.
- · Not scheduled under the Psychoactive Substances Act 2016.
- · No UK marketing authorisation as a medicine.
- · Sold legally as a research chemical when marketed without health claims.
- · Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.
Risks and unknowns
What the literature does not yet show about BPC-157
Known concerns
- No published human RCT data on safety profile or long-term tolerability.
- Most efficacy claims originate from a single research group with limited independent replication.
- Purity of UK research-peptide supply varies. CoA gating and HPLC analysis differ between retailers.
- Cold-chain handling between manufacture and delivery is not standardised across the research-peptide market.
Open questions in the literature
- Optimal route of administration in humans has never been formally studied.
- Pharmacokinetics in humans (half-life, clearance, distribution) are not characterised.
- Long-term effects beyond the duration of typical rodent studies are unknown.
- Whether the proposed angiogenic mechanism is benign in humans with occult neoplastic tissue is not established.
Regulatory note
Not a controlled drug under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. No UK marketing authorisation as a medicine. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Where to learn more
- · PubMed search: BPC-157 returns roughly 200 papers, almost all preclinical.
- · Sikiric P et al. peer-reviewed publications (Zagreb group).
- · UK retailer purity comparison: research peptides UK retailers.
Frequently asked questions
Is BPC-157 legal in the UK?
What does the human evidence show for BPC-157?
What is the regulatory status of BPC-157 in the UK?
What forms is BPC-157 available in?
Where can I learn more about BPC-157?
Where to buy BPC-157 in the UK
Side-by-side price comparison across UK research peptide retailers. Trust Index ranking. Research use only.
Compare UK retailersClinical evidence record
Read the clinical evidence record for BPC-157
Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.
Popular on PeptideClear
Ready to buy
Buy BPC-157 in the UK
UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.